From the Department of Anesthesiology and Intensive Care, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Department of Tisza Research, Danube Research Institute, Centre for Ecological Research, Hungarian Academy of Sciences, Debrecen, Hungary.
Anesth Analg. 2018 Dec;127(6):1344-1350. doi: 10.1213/ANE.0000000000003719.
Certain surgical interventions may require a deep neuromuscular block (NMB). Reversal of such a block before tracheal extubation is challenging. Because anticholinesterases are ineffective in deep block, sugammadex 4 mg/kg has been recommended for the reversal of rocuronium- or vecuronium-induced deep NMB. However, this recommendation requires opening 2 vials of 200 mg sugammadex, which results in an increase in drug costs. Therefore, we sought a less expensive solution for the induction and reversal of deep NMB. Although the optimal dose of sugammadex for antagonism of deep block from pipecuronium has not been established, data pertaining to moderate block are available. Accordingly, we hypothesized that sugammadex 2 mg/kg would be a proper dose to reverse deep pipecuronium block, enabling us to avoid cost increases. In the present study, we compared sugammadex 2 mg/kg with the standard dose of 4 mg/kg for reversal of deep block from pipecuronium.
This single-center, randomized, double-blind, 2 parallel-arms, noninferiority study comprised 50 patients undergoing general anesthesia with propofol, sevoflurane, fentanyl, and pipecuronium. Neuromuscular monitoring was performed with acceleromyography (TOF-Watch SX). Noninferiority margin was specified beforehand as an increase in reversal time of no >10% (corresponding to 1 minute for the primary outcome). When the block spontaneously recovered to posttetanic count 1, the patients randomly received sugammadex 2 or 4 mg/kg, and the time from the injection to the train-of-four (TOF) ratio of 1.0 was measured. Primary outcome was the time to achieve the normalized TOF ratio of 0.9 in a particular patient. Residual or recurrent postoperative NMB was additional end point.
Each patient recovered to the normalized TOF ratio of 0.9. In the 2 mg/kg group, reversal time was 1.73 ± 1.03 minutes (95% confidence interval [CI], 1.33-2.13; n = 25), and in the 4 mg/kg group, reversal time was 1.42 ± 0.63 minutes (mean ± standard deviation) (95% CI, 1.17-1.67; n = 25). The mean difference in reversal times between the 2 groups was 0.31 minutes (95% CI, -0.18 to 0.8), and the upper limit of CI was below the noninferiority margin of 1 minute. Postoperative block did not occur.
The effect of sugammadex 2 mg/kg was noninferior to that of 4 mg/kg in reversing posttetanic count-1 degree pipecuronium block. Sugammadex reversal of deep pipecuronium block appears to be effective.
某些外科手术干预可能需要深度神经肌肉阻滞(NMB)。在气管拔管前逆转这种阻滞是具有挑战性的。由于抗胆碱酯酶在深度阻滞中无效,因此推荐使用 4mg/kg 的琥珀酸舒更葡糖用于逆转罗库溴铵或维库溴铵引起的深度 NMB。然而,这一推荐需要打开 2 瓶 200mg 的琥珀酸舒更葡糖,这会增加药物成本。因此,我们寻求一种更经济的方法来诱导和逆转深度 NMB。尽管尚未确定琥珀酸舒更葡糖拮抗哌库溴铵引起的深度阻滞的最佳剂量,但已有关于中度阻滞的数据。因此,我们假设琥珀酸舒更葡糖 2mg/kg 是逆转深度哌库溴铵阻滞的合适剂量,使我们能够避免成本增加。在本研究中,我们比较了 2mg/kg 琥珀酸舒更葡糖与标准剂量 4mg/kg 用于逆转哌库溴铵引起的深度阻滞。
这项单中心、随机、双盲、2 条平行臂、非劣效性研究纳入了 50 例接受丙泊酚、七氟醚、芬太尼和哌库溴铵全身麻醉的患者。肌电图监测(TOF-Watch SX)。预先指定了非劣效性边界,即逆转时间的增加不超过 10%(相当于主要结局的 1 分钟)。当阻滞自发恢复到强直后计数 1 时,患者随机接受 2 或 4mg/kg 的琥珀酸舒更葡糖,并测量从注射到四个成串刺激(TOF)比值为 1.0 的时间。主要结局是特定患者达到归一化 TOF 比值 0.9 的时间。残留或复发性术后 NMB 是另外的终点。
每位患者均恢复到归一化 TOF 比值 0.9。在 2mg/kg 组,逆转时间为 1.73±1.03 分钟(95%置信区间[CI]:1.33-2.13;n=25),在 4mg/kg 组,逆转时间为 1.42±0.63 分钟(均数±标准差)(95%CI:1.17-1.67;n=25)。两组间逆转时间的平均差异为 0.31 分钟(95%CI:-0.18 至 0.8),CI 的上限低于 1 分钟的非劣效性边界。术后无阻滞发生。
2mg/kg 琥珀酸舒更葡糖的效果在逆转强直后计数-1 度哌库溴铵阻滞方面不劣于 4mg/kg。琥珀酸舒更葡糖逆转深度哌库溴铵阻滞似乎是有效的。